| 000 | 01790 a2200541 4500 | ||
|---|---|---|---|
| 005 | 20250515111420.0 | ||
| 264 | 0 | _c20080320 | |
| 008 | 200803s 0 0 eng d | ||
| 022 | _a1098-4275 | ||
| 024 | 7 |
_a10.1542/peds.2007-1218 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aManlhiot, Cedric | |
| 245 | 0 | 0 |
_aSafety of intravenous immunoglobulin in the treatment of juvenile dermatomyositis: adverse reactions are associated with immunoglobulin A content. _h[electronic resource] |
| 260 |
_bPediatrics _cMar 2008 |
||
| 300 |
_ae626-30 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 | _aAmbulatory Care |
| 650 | 0 | 4 | _aChild |
| 650 | 0 | 4 | _aChild, Preschool |
| 650 | 0 | 4 | _aCohort Studies |
| 650 | 0 | 4 |
_aDermatomyositis _xdiagnosis |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 | _aDrug Administration Schedule |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aFollow-Up Studies |
| 650 | 0 | 4 | _aHospitals, Pediatric |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunoglobulin A _xmetabolism |
| 650 | 0 | 4 |
_aImmunoglobulins, Intravenous _xadministration & dosage |
| 650 | 0 | 4 | _aLogistic Models |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMaximum Tolerated Dose |
| 650 | 0 | 4 | _aMultivariate Analysis |
| 650 | 0 | 4 | _aOntario |
| 650 | 0 | 4 | _aProbability |
| 650 | 0 | 4 | _aRetrospective Studies |
| 650 | 0 | 4 | _aRisk Assessment |
| 650 | 0 | 4 | _aSeverity of Illness Index |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aTyrrell, Pascal N | |
| 700 | 1 | _aLiang, Lisa | |
| 700 | 1 | _aAtkinson, Adelle R | |
| 700 | 1 | _aLau, Wendy | |
| 700 | 1 | _aFeldman, Brian M | |
| 773 | 0 |
_tPediatrics _gvol. 121 _gno. 3 _gp. e626-30 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1542/peds.2007-1218 _zAvailable from publisher's website |
| 999 |
_c17802993 _d17802993 |
||